CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

and continue to experiment with the extended use of therapeutics originally developed to treat the COVID-19 infection, which show mixed results. Additionally, the Centers for Disease Control and ...

The rate of antiviral prescriptions was 67% lower in pregnant than in nonpregnant women, including those with one or more high-risk underlying conditions.

This project award will address a gap for pre-exposure prophylaxis therapeutics that have the potential to provide protection against severe outcomes of COVID-19. Shionogi plans to file an ...